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Objectives: The aim of this study was to determine the temporal relation between the use of antibiotics
and alcohol-based hand rubs (ABHRs) and the incidence of methicillin-resistant Staphylococcus
aureus (MRSA) and Clostridium difficile.
Methods: An interventional time-series analysis was performed to evaluate the impact of two pro-
motion campaigns on the consumption of ABHRs and to assess their effect on the incidence of non-
duplicate clinical isolates of MRSA and C. difficile from February 2000 through September 2006. This
analysis was combined with a transfer function model of aggregated data on antibiotic use.
Results: Consumption of ABHRs correlated with MRSA, but not with C. difficile. The final model
demonstrated the immediate effect of the second hand hygiene promotion campaign and an additional
temporal effect of fluoroquinolone (time lag, 1 month; i.e. antibiotic effect delayed for 1 month), macro-
lide (lag 1 and 4 months), broad-spectrum cephalosporins (lag 3, 4 and 5 months) and piperacillin/tazo-
bactam (lag 3 months) use. The final model explained 57% of the MRSA variance over time. In contrast,
the model for C. difficile showed only an effect for broad-spectrum cephalosporins (lag 1 month).
Conclusions: We observed an aggregate-level relation between the monthly MRSA incidence and the
use of different antibiotic classes and increased consumption of ABHR after a successful hand
hygiene campaign, while no association with ABHR use was detected for C. difficile.
Keywords: cross-infection, prevention and control, alcohol, hand hygiene, methicillin resistance,
Staphylococcus aureus, colitis, intervention model, transfer function model, health policy making
Introduction
Although the role of antibiotics in the epidemiology of
methicillin-resistant Staphylococcus aureus (MRSA) and
Clostridium difficile has been extensively studied, many contro-
versies persist.1,2 In particular, it remains unclear to what extent
antibiotic stewardship may decrease MRSA or C. difficile acqui-
sition within hospitals.
Previous studies have suggested that time-series analysis may
be an accurate tool to describe the association between
in-hospital antibiotic consumption and the incidence of
antibiotic-resistant pathogens, including C. difficile.3 Only a few,
however, included the effect of the time-varying use of alcohol-
based hand rubs (ABHRs), which may have an important effect
on cross-transmission.4 – 8 This is particularly important, since
some experts have suggested that the promotion of ABHR may
increase the spread of C. difficile due to their lack of sporicidal
activity.9,10
At the University of Geneva Hospitals (HUG), MRSA has
reached endemic levels. Despite the positive impact of a hospi-
talwide campaign promoting the use of bedside hand antisepsis
on the prevalence of MRSA between 1994 and 1997,4,11 we
have observed an increase in the number of patients colonized
and/or infected by MRSA since 1998. In response to this worri-
some trend, two campaigns were launched to reinforce compli-
ance with standard precautions and hand hygiene.
Hitherto, we have assessed neither the dynamic effect of
these campaigns nor the influence of antibiotic selection
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pressure on the local epidemiology of MRSA and C. difficile. In
this paper, we attempted to determine the temporal association
between antibiotic use, the use of ABHRs and the occurrence of
MRSA and C. difficile at our institution. In particular, we
assessed whether the isolation of MRSA and C. difficile was
temporarily associated with the in-hospital use of several classes
of antimicrobial agents.
Methods
Setting
The HUG are a 2200 bed primary and tertiary healthcare centre,
including 37 adult intensive care unit beds, 923 acute care beds, 761
rehabilitation, geriatric and long-term care beds, 129 paediatric beds
and 348 psychiatric beds, with 45 000 admissions and over
850 000 outpatient visits each year.
Interventions
Antibiotic usage. During the study period, there was no institutional
policy regarding the antibiotic use at HUG. Education and other
methods to improve the antimicrobial use have not been
implemented on a systematic basis. The therapeutics committee pro-
vides some recommendations regarding costly antibiotics. However,
restriction is rare. Moreover, at the pharmacy level, refusal to dis-
pense a drug is uncommon and physicians can prescribe any antimi-
crobial agent available at HUG.
Hand hygiene. Since 1994, an ABHR formula (Hopirubw) for hand
antisepsis produced locally by the hospital pharmacy has been
widely available to staff in the form of pocket-sized bottles and has
been used throughout the hospital as the agent of choice for hand
hygiene.12,13 In spring 2003, a programme applying social marketing
theory was initiated for the homogeneous implementation of stan-
dard precautions and isolation precautions under the registered
trademark of ‘VigiGermew’.13 Although VigiGermew mentioned
hand hygiene as an element of standard precautions, it did not target
the promotion of ABHR in particular. As part of a Swiss national
hand hygiene promotion campaign and the Global Patient Safety
Challenge entitled ‘Clean care is safer care’, and organized by the
World Health Organization (WHO),14 the second initiative started in
autumn 2005 with an exclusive focus on the frequent and proper use
of ABHR.
MRSA and C. difficile control policy. The institutional strategy to
control MRSA is based on different components that have been
described previously.11,15,16 In brief, these include systematic
on-admission screening and pre-emptive isolation in the critical care
setting, isolation in single rooms, when available, screening of
roommates as soon as a new MRSA carrier has been identified, a
computerized laboratory alert system17 and topical decolonization of
known MRSA carriers without risk factors for persistent carriage.18
Hospital policy to prevent the spread of C. difficile comprises
several evidence-based elements19: contact isolation, thorough
environmental cleaning with bleach and adequate antibiotic treat-
ment. For sporadic cases, the use of ABHR after glove removal is
not discouraged. Figure 1 summarizes the details of the study popu-
lation, definitions and infection control policies implemented during
the study period, as proposed by the ORION statement.20
Data collection
Monthly aggregated data of all antimicrobial drugs delivered to the
entire institution were provided by the pharmacy department from
February 2000 to September 2006. Paediatrics and psychiatry were
excluded. Following the WHO’s recommended metric, the defined
daily dose (DDD), i.e. the assumed average maintenance dose per
day for a drug used for its main indication in an adult, antibiotic
usage was expressed as monthly aggregated DDD and normalized
per 100 patient-days (antibiotic use density).21 Monthly use of litres
of ABHR were also collected and normalized per 100 patient-days,
Setting: 2200 bed primary and tertiary care teaching
hospital in Switzerland. Paediatrics and psychiatry were
excluded from this analysis. Infection control programme
with one director, three associate hospital epidemiologists
and nine full-time infection control nurses. 
Dates:
February 2000 to
September 2006. 
Population characteristic: Mean hospitalization days, 51 524 per
month (range, 48 102–55 128). Endemic MRSA, with clone
ST228 representing the predominating strain since 1999.
Sporadic Clostridium difficile with occasional small clusters. 
Infection control campaigns during the study: HUG launched two hospitalwide promotion campaigns; VigiGerme®  in spring 2003 and ‘Clean
care is safer care’ in autumn 2005 (including hand hygiene observations of healthcare personnel).
Antibiotic use: During the study period, there was no institutional antibiotic policy; physicians could prescribe any antimicrobial agent available at
HUG. Beginning in March 2006, HUG experienced a shortage of cefepime leading to an increase in piperacillin/tazobactam use. 
MRSA control policy: Systematic pre-emptive isolation in the critical care setting; contact isolation of MRSA carriers in single rooms, when
available; use of dedicated material (e.g. gown, gloves, mask if indicated); computerized laboratory alert system; topical decolonization (nasal
mupirocin ointment and chlorhexidine body washing) of known MRSA carriers without risk factors for persistent carriage.18
MRSA screening policy: Systematic on-admission screening in the critical care setting; screening of room-mates as soon as a new MRSA carrier 
has been identified; universal MRSA on-admission screening from January to August 2003 in the entire hospital28 and from October 2004 to May 
2006 in selected surgical wards.16 Screening sites: nose, groin, skin lesions, infected sites. 
C. difficile control policy: Contact isolation, thorough environmental cleaning with bleach and adequate antibiotic treatment.
Definition of MRSA and C. difficile incidence: Number of clinical isolates per 100 patient-days, eliminating duplicates and surveillance swabs. 
Figure 1. Population, setting, dates, definitions, antibiotic policy, promotion campaigns and infection control interventions. MRSA, methicillin-resistant S.
aureus; HUG, Geneva University Hospitals; ST, sequence type.
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as well as the hospital occupation rate expressed as occupied beds
per 100 patient-days.
Monthly aggregated data on the number of new clinical MRSA
isolates (excluding surveillance swabs and duplicates) were col-
lected and expressed as an incidence density, i.e. the number of
MRSA cultures per 100 patient-days.11 For C. difficile occurrence,
we used equivalent monthly incidence data based on laboratory-
based surveillance.
Statistical analysis
Since temporally sequenced observations on MRSA and C. difficile
are not independent, applying simple regression analysis would be
inappropriate to evaluate these data.22 Therefore, time-series analy-
sis was used to examine the trends and autocorrelations over time,
including characteristics for each explanatory variable and the out-
comes of interest (MRSA and C. difficile incidence). We chose
autoregressive integrated moving average (ARIMA) models using
the Box–Jenkins method for analysis, which allow the stochastic
dependence of consecutive data to be modelled.23 Moreover, the
methodology developed by Lo´pez-Lozano and Monnet was applied
to our data.3,24,25
We built an intervention model to determine if the two pro-
motion campaigns significantly changed ABHR consumption. In an
intervention model, the time series is constituted by an indicator
variable containing discrete values. It may change due to an inter-
vention interrupting the stationary evolution of the series, which, in
the absence of the intervention, is usually assumed to be a pure
ARIMA process.23 To evaluate the effect of the two campaigns, we
created dummy variables, with 0 and 1 representing pre-intervention
and post-intervention periods, respectively.
Using two transfer function models, we assessed the association
between the ‘response’ time series of the monthly incidence density
of MRSA and C. difficile in terms of non-duplicate clinical isolates
per 100 patient-days and the ‘explanatory’ time series of antibiotic
usage, bed occupation rate and ABHR use (intervention model),
taking into account the possible time delays of the effects (antibiotic
and ABHR use) of up to 5 months.
A transfer function model consists of modelling a time series as
a function of its past values and random errors. For each individual
series, we identified and fitted an ARIMA model according to Box
and Jenkins and therefore performed the following steps.23 We first
checked if the series were stationary (i.e. having a constant mean
and variance), then identified the model by determining the ARIMA
model orders (p,d,q) with the autocorrelation and partial auto-
correlation, then estimated the model parameters by unconditional
least squares method and finally checked the adequacy of the model
and statistical significance of the parameters. Among different
models, we chose the most parsimonious one with the fewest
parameters. The generated coefficient (R2) measures the overall fit
of the regression line, expressing how close the points are to the
estimated regression line in the scatter plot. In other terms, R2 is
the fraction of the variance of the dependent variable explained by
the regression model.
After identification of the transfer function models, we deter-
mined the cross-correlation function estimating the correlations
between the antibiotic use series at different time lags, the ABHR
intervention model, occupation rate and the MRSA and C. difficile
series. Significance tests for parameter estimates were used to elim-
inate the unnecessary terms in the model. A P value of ,0.05 was
considered to be statistically significant. All statistical analyses were
performed with EViews 3 software (QMS, Irvine, CA, USA).
Results
Incidence of MRSA and C. difficile
Figure 2 shows the monthly incidence of non-duplicate MRSA
and C. difficile clinical isolates per 100 patient-days. The
average monthly MRSA incidence was 0.15 clinical isolates per
100 patient-days, varying from 0.09 to 0.21. No overall trend
was observed throughout the period (P ¼ 0.71). We identified an
ARIMA model with one significant autoregressive term of order
(lag) 1 month (R2 ¼ 0.25).
During the same period, the monthly incidence of C. difficile
was 0.027 isolates per 100 patient-days, varying from 0.004 to
0.054, without any trend (P ¼ 0.82). From these monthly data,
we built a second ARIMA model, which showed an autoregres-
sive term of order (lag) 1 month and a moving average of order
1 (R2 ¼ 0.22).
Rates of antibiotic use
Monthly rates of antimicrobial use are detailed in Table 1 and
Figure 3. The average antimicrobial use over the study period
was 33 DDD/100 patients-days and did not change over time
(P ¼ 0.29). Penicillins (WHO class, J01C) were the most widely
used antibiotic class (30%; pooled rate, 9.84 DDD/100 patient-
days), followed by cephalosporins and carbapenems (J01D:
25%; pooled rate, 8.25 DDD/100 patient-days), fluoroquinolones
(J01M), macrolides (J01F), trimethoprim/sulfamethoxazole
(J01E) and glycopeptides (J01X) (Table 1).
Intervention model of the use of ABHRs
Consumption of ABHRs increased over the study period, from
an average of 1.303 L per 100 patient-days in 2001 to 2.016 L
per 100 patient-days in 2006. We identified an ARIMA model
(R2 ¼ 0.95) with two significant autoregressive terms of order
(lag) 1 and 3 months. The intervention model detailed in
Table 2 showed statistically significant effects at a contempora-
neous time of the VigiGermew campaign and the ‘Clean care is
safer care’ campaign.
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Figure 2. Monthly incidence of non-duplicate clinical isolates of C. difficile
and MRSA, per 100 patient-days on the left-hand scale and litres of ABHRs
per 100 patient-days on the right-hand scale. University of Geneva Hospitals,
February 2000 to September 2006. The two peaks of ABHR use in 2004 and
2006 represent artificial increases due to the massive, single-time over-
ordering of ABHRs by the adult intensive care units.
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Final models
Methicillin-resistant S. aureus. We built a first transfer function
model by combining the analysis on hand rub consumption with
monthly rates of antibiotic use, and then determined their effect
on MRSA incidence. The generated model showed an autore-
gressive term of order 1 and a moving average of order 1 with
an R2 of 0.57, which means that the overall model explains 57%
of the MRSA variance (Figure 4).
The estimated parameters obtained by unconditional least
square method are shown in Table 3. In this model, there are six
statistically significant explanatory variables, fluoroquinolone
use (lag 1 month), macrolide use (lag 1 and 4 months), third-
generation cephalosporin use (lag 4 and 5 months), cefepime
use (lag 3 months), piperacillin/tazobactam use (lag 3 months)
and the ‘Clean care is safer care’ campaign at a contempora-
neous time. Neither the VigiGermew campaign, nor the bed
occupancy rate or the use of other agents (amoxicillin,
amoxicillin/clavulanic acid, cefuroxime, carbapenem,
clindamycin, trimethoprim/sulfamethoxazole and glycopeptides)
was statistically significant in this model. All of the included
parameter estimates for antibiotic use were positive, meaning
that an increase of 1 U would increase MRSA incidence. Thus,
an increase of 1 DDD/100 patient-days of antibiotic use will be
associated with an increase in the number of MRSA isolates
from the current level, i.e. 0.01 for fluoroquinolones, 0.03 for
macrolides, 0.03 for third-generation cephalosporins, 0.01 for
cefepime and 0.04 for piperacillin/tazobactam. Conversely, the
second hand hygiene campaign reduced the MRSA incidence;
1 L of hand rub per 100 patient-days decreased the MRSA by
0.03 isolates per 100 patient-days.
Clostridium difficile. We built another transfer function model
for C. difficile incidence. This model shows an autoregressive
term of order 1, where R2 was low (0.17), meaning that the
overall model explains only 17% of the C. difficile variance. In
this model, there was only one statistically significant
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Figure 3. Monthly rates of antimicrobial use in DDDs per 100 patient-days. University of Geneva Hospitals, February 2000 to September 2006. The
abbreviations shown (e.g. J01X) correspond to the WHO nomenclature of the different classes of antimicrobial agents.
Table 1. Monthly time series of antimicrobial use and temporal relation with MRSA and C. difficile, February 2000 to September 2006
WHO
classification Antimicrobial use
Average monthly
use (min–max)
Percentage
of total use Trend P
Temporal relation
with MRSA
Temporal
relation with
C. difficile
J01C amoxicillin/clavulanate 6.39 (4.50–9.26) 19 20.0242 0.001 no no
amoxicillin 3.22 (1.89–4.28) 10 0.0059 0.026 no no
piperacillin/tazobactam 0.23 (0.01–1.30) 1 0.0098 ,0.001 yes no
J01D cefuroxime 2.46 (1.78–3.39) 7 20.0002 0.926 no yes
third-generation cephalosporins 2.87 (1.79–4.18) 9 0.0132 ,0.001 yes yes
cefepime 1.82 (0–2.77) 6 20.0372 0.015 yes yes
carbapenems 1.10 (0.61–1.65) 3 0.9259 0.336 no no
J01M fluoroquinolones 5.41 (4.06–7.02) 16 20.0023 0.478 yes no
J01F macrolides 2.27 (1.00–3.72) 7 0.0040 0.033 yes no
clindamycin 0.58 (0.06–1.27) 2 0.0052 ,0.001 no no
J01E trimethoprim/sulfamethoxazole 1.01 (0.47–1.50) 3 0.0033 0.004 no no
J01X glycopeptides 0.84 (0.33–1.25) 3 20.0019 0.003 no no
MRSA, methicillin-resistant S. aureus; WHO, World Health Organization.
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explanatory variable, i.e. the use of broad-spectrum cephalospor-
ins (lag 1 month; parameter, 0.0045; SE, 0.002; P ¼ 0.026). In
contrast, neither the use of ABHRs nor other antibiotic classes
showed statistically significant correlations with C. difficile
incidence.
Discussion
The main result of this study is that we found not only a tem-
poral relation between MRSA incidence and the consumption of
several classes of antibiotics, but also demonstrated the effi-
ciency of a campaign focusing on hand hygiene promotion
through proper use of ABHRs. The final model allows quantifi-
cation of the effect of antibiotic use on MRSA and estimated the
delay between variations in antimicrobial use and resistance.
The transfer function model on MRSA explains 57% of the var-
iance which is relatively high for this type of ecological analy-
sis. Yet, 43% of the variation remain unexplained and could be
linked to patient factors, infection control practices and environ-
mental characteristics. In contrast, our results did not find any
correlation between the increasing use of ABHRs and the inci-
dence of C. difficile at our institution. The model on C. difficile
explains only 17% of the variation, thus rejecting a detrimental
effect of ABHR use.
Different types of studies have been used to quantify the
association between antibiotic use and the incidence of MRSA
or C. difficile in hospitalized patients. These studies included
outbreak reports, prevalence surveys, controlled trials, meta-
analyses and prospective or retrospective cohort studies based on
analyses of individual patient-level data or aggregated data.7,26–34
The different methodological approaches are not mutually trans-
posable, and the lack of uniformity makes the comparison of
different studies difficult.2 Our findings confirm, however, the
important effect of different antibiotic classes on the selection
of MRSA (e.g. cephalosporins, fluoroquinolones), reported in
previously published time-series analyses.7,25,35
We confirmed the previous reports about the impact of
improved hand hygiene practices on MRSA.4,6 Our models show
an immediate effect of increasing ABHR use after the second
campaign; in contrast, we observed lag effects up to 5 months of
antibiotic usage on MRSA incidence that are not plausible from
an epidemiological perspective, particularly in a hospital in
which the mean stay is 8 days. However, it has been shown
that environmental contamination may be sustained. An
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Figure 4. Transfer function model with analysis of MRSA incidence.
University of Geneva Hospitals, February 2000 to September 2006.
Table 3. Multivariate transfer function model for incidence of
MRSA; University of Geneva Hospitals, February 2000 to
September 2006
Variable
Laga
(months)
Parameterb
(SE)
t
statistic P
Constant 20.079 (0.030) 22.62 0.011
Fluoroquinolones 1 0.010 (0.004) 2.71 0.009
Macrolides 1 0.014 (0.004) 3.61 ,0.001
Macrolides 4 0.012 (0.004) 3.19 0.002
Third-generation
cephalosporins
4 0.014 (0.006) 2.15 0.035
Third-generation
cephalosporins
5 0.015 (0.007) 2.21 0.031
Cefepime 3 0.014 (0.006) 2.56 0.013
Piperacillin/
tazobactam
3 0.041 (0.014) 2.97 0.004
‘Clean care is safer
care’ campaign’s
effect
0 20.032 (0.005) 25.81 ,0.001
Autoregressive termc 1 0.546 (0.168) 3.24 0.002
Moving average
termd
1 20.732 (0.164) 24.46 ,0.001
The transfer function model can also be presented as the following equation:
MRSA(t) ¼ 20.08 þ 0.54 MRSA(t2 1) þ 0.01 fluoroquinolones þ 0.03
macrolides þ 0.03 third-generation cephalosporins þ 0.014 cefepime þ 0.04
piperacillin/tazobactam2 0.03 second hand hygiene campaign.
aDelay necessary to observe the effect.
bSize and direction of the effect.
cThe autoregressive term represents the past value of the resistance.
dThe moving average term represents disturbances or abrupt changes of
resistance.
Table 2. Intervention model analysing the effect of two promotion
campaigns on ABHR use; University Hospitals of Geneva, February
2000 to September 2006
Variable
Parameter
(SE)a
t
statistic P value
Constant 1.362 (0.044) 31.22 ,0.0001
VigiGermew campaign (spring
2003)
0.390 (0.049) 8.03 ,0.0001
‘Clean care is safer care’
campaign (autumn 2005)
0.189 (0.057) 3.34 0.0013
ICU delivery 1b 0.921 (0.071) 12.90 ,0.0001
ICU delivery 2b 0.903 (0.076) 11.91 ,0.0001
AR (order 1)c 0.236 (0.111) 2.13 0.0365
AR (order 3)c 0.447 (0.107) 4.17 0.0001
aSize and direction of the effect.
b‘ICU deliveries’ 1 and 2 represent the artificial increases of ABHR use due
to massive over-ordering and exceptional delivery of large quantities of
alcohol-based hand gels to the adult intensive care units (ICUs) in 2004 and
2006.
cThe autoregressive (AR) term represents the past value of ABHR use at
months 1 and 3.
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interventional cohort study reported a 6 month delay in the
decline of C. difficile-associated diarrhoea after virtual withdra-
wal of all cephalosporins which may reflect a slowly diminish-
ing environmental reservoir.36 To a lesser degree, this
phenomenon may also apply for MRSA. As shown by two
recent studies, withdrawal of fluoroquinolones or reduction of
macrolide use may cause a measurable ecological effect on
MRSA incidence only after several months.7,31
Modelling drug use versus susceptibility relations is a useful
tool for complementing traditional surveillance and epidemiolo-
gical studies. In our institution, it helped policy-making by esti-
mating which drugs have an important impact on MRSA
acquisition. Thus, antibiotic stewardship strategies could be tai-
lored to the results of this multivariate time-series analysis,
which allows various explanatory variables to be examined in
parallel. Moreover, this analysis allowed external benchmarking.
In our hospital, compared with other institutions in high-income
countries, the volume of antibiotic use is below average (despite
the absence of an institutional antibiotic policy) and the con-
sumption of ABHRs is high.6,12,37,38
Our study has several limitations. First, group-level analyses
of aggregate data may be distorted by ecological bias.39
Modelling of individual patient-level data or multilevel data
should complement time-series analyses to exclude spurious
findings.30 The availability of electronic prescribing records may
allow us to perform combined analyses at both individual and
group levels.40 Second, DDD represents a technical unit that
may not represent the true prescription data and may be wrong
in children, patients with renal impairment and other
co-morbidities.38 Nevertheless, this method is still the most
widely applied because of its potential for internal and external
benchmarking. Third, we did not exclude the clinical MRSA
isolates retrieved within 48 h after admission. This decision was
based on the knowledge that community MRSA is still very rare
in Geneva and that the vast majority of MRSA-infected patients
detected upon admission had a previous hospital stay at HUG
and were infected by a single MRSA clone (ST 228-MRSA-I)
endemic at HUG.28,41,42 Finally, the VigiGermew campaign did
not have a significant effect on MRSA incidence in the multi-
variate analysis. This finding could be explained either by the
neutralizing effect of temporarily increased use of fluoroquino-
lones or by the fact that this campaign was not focused on hand
hygiene promotion and targeted many other aspects of standard
and contact precautions. In contrast, the second campaign
‘Clean care is safer care’ promoted a user-centred concept of
hand hygiene.43
In conclusion, we found an aggregate-level relationship
between monthly MRSA incidence and the consumption of
ABHRs and different antibiotic classes, while no association
with increased hand rub use was detected for C. difficile.
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